A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-BLIND, RANDOMISED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND RAISED TRANSAMINASES

被引：19
|
作者：
Shiffman, M. [1 ]
Freilich, B. [2 ]
Vuppalanchi, R. [3 ]
Watt, K. [4 ]
Burgess, G. [5 ]
Morris, M. [5 ]
Sheedy, B. [5 ]
Schiff, E. [6 ]
机构：
[1] Bon Secours Hlth Syst Richmond & Newport News, Liver Inst Virginia, Richmond Newport News, VA USA
[2] Kansas City Res Inst, Kansas City, KS USA
[3] Indiana Univ Sch Med, Div Gastroenterol & Hepatol 3, Indianapolis, IN 46202 USA
[4] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[5] Conatus Pharmaceut Inc, San Diego, CA USA
[6] Univ Miami, Div Hepatol, Miami, FL USA
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30191-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LP37
引用
收藏
页码：S282 / S282
页数：1
相关论文
共 50 条
  • [1] Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Chong, Clara Yieh Lin
    Orr, David
    Plank, Lindsay D.
    Vatanen, Tommi
    O'Sullivan, Justin M.
    Murphy, Rinki
    NUTRIENTS, 2020, 12 (04)
  • [2] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS
    Harrison, Stephen A.
    Goodman, Zachary D.
    Jabbar, Abdul
    Younes, Ziad
    Vemulapalli, Ravi
    Freilich, Bradley L.
    Sheikh, Muhammad Y.
    Schattenberg, Joern
    Kayali, Zeid
    Zivony, Adam Seth
    Sheikh, Aasim M.
    Garcia-Samaniego, Javier
    Satapathy, Sanjaya Kumar
    Therapondos, George
    Mena, Edward A.
    Schuppan, Detlef
    Robinson, James M.
    Chan, Jean Lin
    Hagerty, David
    Sanyal, Arun J.
    HEPATOLOGY, 2019, 70 : 43A - 44A
  • [3] Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
    Kessoku, Takaomi
    Imajo, Kento
    Kobayashi, Takashi
    Ozaki, Anna
    Iwaki, Michihiro
    Honda, Yasushi
    Kato, Takayuki
    Ogawa, Yuji
    Tomeno, Wataru
    Kato, Shingo
    Higurashi, Takuma
    Yoneda, Masato
    Kirikoshi, Hiroyuki
    Kubota, Kazumi
    Taguri, Masataka
    Yamanaka, Takeharu
    Usuda, Haruki
    Wada, Koichiro
    Kobayashi, Noritoshi
    Saito, Satoru
    Nakajima, Atsushi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (11): : 996 - 1007
  • [4] Quercetin supplementation in non-alcoholic fatty liver disease A randomized, double-blind, placebo-controlled clinical trial
    Hosseinikia, Mahboobe
    Oubari, Farhad
    Hosseinkia, Roghaye
    Tabeshfar, Zibaneh
    Salehi, Mohammad Gharib
    Mousavian, Zeinab
    Abbasi, Mehrnaz
    Samadi, Mehnoosh
    Pasdar, Yahya
    NUTRITION & FOOD SCIENCE, 2020, 50 (06): : 1279 - 1293
  • [5] Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial
    Chachay, V. S.
    Martin, J. H.
    Prins, J. B.
    Whitehead, J. P.
    O'Moore-Sullivan, T. M.
    Lee, P.
    Franklin, M.
    Klein, K.
    Taylor, P. J.
    Ferguson, M.
    Coombes, J. S.
    Thomas, G. P.
    Cowin, G. J.
    Kirkpatrick, C. M. J.
    Macdonald, G. A.
    Hickman, I. J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 78 - 79
  • [6] Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial
    Mofidi, Fatemeh
    Poustchi, Hossein
    Yari, Zahra
    Nourinayyer, Babak
    Merat, Shahin
    Sharafkhah, Maryam
    Malekzadeh, Reza
    Hekmatdoost, Azita
    BRITISH JOURNAL OF NUTRITION, 2017, 117 (05) : 662 - 668
  • [7] The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial
    Jazayeri-Tehrani, Seyed Ali
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Qorbani, Mostafa
    Alavian, Seyed Moayed
    Daneshi-Maskooni, Milad
    Hosseinzadeh-Attar, Mohammad-Javad
    NANOMEDICINE JOURNAL, 2018, 5 (02) : 67 - 76
  • [8] The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
    Mirhafez, Seyed Reza
    Azimi-Nezhad, Mohsen
    Dehabeh, Maryam
    Hariri, Mitra
    Naderan, Ronika Danesh
    Movahedi, Ali
    Abdalla, Mohammed
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    PHARMACOLOGICAL PROPERTIES OF PLANT-DERIVED NATURAL PRODUCTS AND IMPLICATIONS FOR HUMAN HEALTH, 2021, 1308 : 25 - 35
  • [9] Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial
    Kyungsun Han
    Ojin Kwon
    Hyo-ju Park
    So-Young Jung
    Changsop Yang
    Chang-Gue Son
    Trials, 21
  • [10] Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial
    Han, Kyungsun
    Kwon, Ojin
    Park, Hyo-Ju
    Jung, So-Young
    Yang, Changsop
    Son, Chang-Gue
    TRIALS, 2020, 21 (01)
12345